Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

J&J Gets CHMP Positive Option for Preventive Ebola Vaccine Regimen

share with twitter share with LinkedIn share with facebook
05/29/2020 | 08:54am EDT

By Colin Kellaher

 

Johnson & Johnson on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of its investigational Ebola vaccine regimen for the prevention of the disease caused by the Zaire ebolavirus species.

J&J said the two-dose regimen is designed to support preventive vaccination in countries that are at risk of Ebola outbreaks, as well as for other at-risk groups, such as healthcare and lab workers.

The company said the regimen includes Ad26.ZEBOV as the first dose, based on its Janssen Pharmaceutical Cos. unit's proprietary AdVac viral vector technology, and MVA-BN-Filo as the second dose, based on Bavarian Nordic A/S's MVA-BN technology, administered roughly eight weeks later.

"Today's CHMP opinion confirms the potential of Janssen's vaccine technology, which we hope to apply against a range of established and emerging epidemic threats, including the Covid-19 pandemic," J&J said.

The regimen now awaits approval from the European Commission, which generally follows the CHMP's recommendations.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 


Stocks mentioned in the article
ChangeLast1st jan.
BAVARIAN NORDIC A/S 2.77% 170.8 Delayed Quote.-0.38%
HOPE, INC. -2.64% 5540 End-of-day quote.72.05%
JOHNSON & JOHNSON -0.85% 137.19 Delayed Quote.-5.95%
THE NEW HOME COMPANY INC. 3.45% 5.4 Delayed Quote.15.88%
VECTOR INC. 0.48% 208 End-of-day quote.-36.78%
VECTOR INC. -2.35% 914 End-of-day quote.-14.26%
share with twitter share with LinkedIn share with facebook
All news about JOHNSON & JOHNSON
03:01aKARO PHARMA : publishes third-quarter report 2020 and resolves on sale of own sh..
AQ
10/28Combined Market Cap of Five Largest MedTech Companies Surged by $40bn YoY
AQ
10/28JOHNSON & JOHNSON : Thinking about trading options or stock in Microsoft, First ..
PR
10/27JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA for New Indication t..
AQ
10/27JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA for New Indication t..
AQ
10/26WALL STREET STOCK EXCHANGE : US companies under China sanctions, Many acquisitio..
10/26JOHNSON & JOHNSON : Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COV..
AQ
10/24AstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to..
RE
10/23JOHNSON & JOHNSON : Pivotal Study of J&J's Covid-19 Vaccine to Resume, Company S..
DJ
10/23JOHNSON & JOHNSON : Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COV..
PU
More news
Financials (USD)
Sales 2020 81 814 M - -
Net income 2020 15 967 M - -
Net Debt 2020 7 344 M - -
P/E ratio 2020 22,6x
Yield 2020 2,90%
Capitalization 361 B 361 B -
EV / Sales 2020 4,50x
EV / Sales 2021 4,09x
Nbr of Employees 132 200
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 165,22 $
Last Close Price 137,19 $
Spread / Highest target 31,2%
Spread / Average Target 20,4%
Spread / Lowest Target 1,32%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-5.95%361 159
ROCHE HOLDING AG-6.18%276 926
PFIZER INC.-9.95%196 991
MERCK & CO., INC.-16.56%192 678
NOVARTIS AG-21.82%179 655
NOVO NORDISK A/S9.01%154 697